Health & Longevity

Early trials reported tumor responses or disease control in treatment-resistant metastatic breast cancer, especially triple-negative disease; lasting patient benefit remained uncertain.

After engineered T-cell therapy, one man's lymphoma returned. Scans showed no active lymphoma during pembrolizumab, but lung inflammation cut treatment short.

A 2021 review describes camrelizumab's specified uses in China for Hodgkin lymphoma and advanced liver cancer, alongside research into other tumors.

A 2021 paper examines ways to alter fibrous tissue around tumors. One approach eased immune resistance in preclinical models without producing a lasting cure.

For acute lymphoblastic leukemia, a 14-study review found better survival and remission odds with antibody treatment than with chemotherapy alone.

A 2021 paper explains how antibodies enlist natural killer cells and macrophages against myeloma, and why immune-modulating drugs might reinforce that response.

Early cancer vaccine studies in children reported immune responses but few clinical responses. Target selection and tumor suppression may help explain the gap.

A review estimated that PD-L1 test results differed in about one in five primary tumor–metastasis pairs, raising questions about relying on the original biopsy alone.

Across 19 studies, added immune-cell treatment was linked to more complete tumor responses and lower rates of death or progression during follow-up.